Synlogic, Inc. (SYBX)
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
$17.54M
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
84.00
Cambridge, MA
Sep 30, 2015
-0.32
$-4.63
4.80
5.15
-6,383.28%
-2.33
0.02
2.70
18.01
4.80
-79.95%
-82.72%
Similar stocks (21)
Edgewise Therapeutics, Inc.
EWTX
4D Molecular Therapeutics, Inc.
FDMT
Erasca, Inc.
ERAS
Stoke Therapeutics, Inc.
STOK
Third Harmonic Bio, Inc.
THRD
C4 Therapeutics, Inc.
CCCC
Monte Rosa Therapeutics, Inc.
GLUE
Generation Bio Co.
GBIO
Kronos Bio, Inc.
KRON
Passage Bio, Inc.
PASG
Protara Therapeutics, Inc.
TARA
AN2 Therapeutics, Inc.
ANTX
Surrozen, Inc.
SRZN
SAB Biotherapeutics, Inc.
SABS
Monopar Therapeutics Inc.
MNPR
Vaccinex, Inc.
VCNX
Processa Pharmaceuticals, Inc.
PCSA
Fresh Tracks Therapeutics, Inc.
FRTX
Galera Therapeutics, Inc.
GRTX
Comera Life Sciences Holdings, Inc.
CMRA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (21)
Edgewise Therapeutics, Inc.
EWTX
4D Molecular Therapeutics, Inc.
FDMT
Erasca, Inc.
ERAS
Stoke Therapeutics, Inc.
STOK
Third Harmonic Bio, Inc.
THRD
C4 Therapeutics, Inc.
CCCC
Monte Rosa Therapeutics, Inc.
GLUE
Generation Bio Co.
GBIO
Kronos Bio, Inc.
KRON
Passage Bio, Inc.
PASG
Protara Therapeutics, Inc.
TARA
AN2 Therapeutics, Inc.
ANTX
Surrozen, Inc.
SRZN
SAB Biotherapeutics, Inc.
SABS
Monopar Therapeutics Inc.
MNPR
Vaccinex, Inc.
VCNX
Processa Pharmaceuticals, Inc.
PCSA
Fresh Tracks Therapeutics, Inc.
FRTX
Galera Therapeutics, Inc.
GRTX
Comera Life Sciences Holdings, Inc.
CMRA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (5)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%